Press conference: Rheumatic Heart Disease a forgotten but devastating disease
|
|
- Roy Lamb
- 8 years ago
- Views:
Transcription
1 Chairpersons: Bongani M. Mayosi Jonathan Carapetis Press conference: Rheumatic Heart Disease a forgotten but devastating disease
2 RHD The Real World Situation L.Zühlke, G.Karthikeyan, M.Engel, B.Cupido, A.Joachim, R.Daniels S.Rangarajan, S.Yusuf, K.Teo, B.Mayosi. for the Rheumatic Heart Disease Global Registry (REMEDY) Investigators
3
4 Burden of Disease:Heart Failure Mayosi, B et al Heart % 3% 12% 35% CHD Renal 17% Rheumatic Heart Disease 26% CMO EMF Ellis J et al Trop Doct 2007 Tamponade
5 Gunther et al The Lancet 2006 Diao M et al Arch Cardiovasc Dis. 2011
6 RhEuMatic Heart Disease RegistrY - REMEDY Rationale and Design Prospective, international (Africa and India), hospital-based registry; follow-up and outcome ascertainment at two-year follow-up N = 3000 The full study will aim to enroll 10,000 patients. Main objectives Karthikeyan G et al. Rationale and design of a Global Rheumatic Heart Disease Registry: The REMEDY study. American Heart Journal To describe demographic and disease characteristics of contemporary patients To describe prevailing treatment patterns (Focus on adherence to and quality of oral anticoagulation, and adherence to secondary penicillin prophylaxis) Major outcomes (all-cause mortality, stroke/systemic embolism, major bleeding, RF)
7 Preliminary Results: Previous History n=690 15% 13% 10% 6% 6% 6% 5% 1% 2% 0% Infective Endocarditis Major Bleeding Peripheral Embolism Stroke Valvulopasty Previous surgery
8 Preliminary Results- n=690 Mild Moderate Severe % NYHA 3 or 4 60 % diagnosed with Congestive Heart Failure AR AS MR MS TS
9 Oral Anticoagulants Prescribed Preliminary Results- n=690 Awareness of Goal INR 55.3% 44.7% Yes No 65% 35% Yes No Measurements of INR in past 6 months 40% 30% 29% 33% 24% 20% 14% 10% 0% or more none
10 RhEuMatic Heart Disease RegistrY - REMEDY Preliminary data Young patients (mean age) 30 years Proportion with AF 31.6% High-risk population 4.4% (15/341) all-cause mortality at 10-month follow-up Mean age of death: 50 years
11 In conclusion There is an irrefutable burden of disease relating to RHD in Africa and middle and low-income countries. REMEDY presents an opportunity for collaboration, in describing and documenting the course of a neglected disease. Initial results indicate significant disease burden and serious morbidity. There are important gaps in the prescription of and adherence to guideline-recommended treatments. This presents opportunities for focused intervention. REMEDY will be a source of valuable information for governments in formulating policy and guidelines for the control and treatment of RHD.
12 Thank you
13 Dr. Antonio Grimaldi, M.D. Cardiovascular and Thoracic Department, San Raffaele Scientific Hospital, Milan, Italy Rheumatic Heart Disease Remains a Major Cause of Heart Failure in Developing Nations The Ugandan Experience
14 BACKGROUND The increasing global crisis in Non-Communicable Diseases (heart disease, stroke, cancer, diabetes, etc.), is a barrier to UN development goals including poverty reduction, health equity, economic stability, and human security (Lancet 2011). In Africa, cardiovascular diseases are the second leading cause of mortality and the first under the age of 50 years. Uganda, like many other african countries, has an accelerated epidemiological transition with a marked increase in cardiovascular non-communicable diseases (Mayosi, Science 2009).
15 BACKGROUND Heart failure (HF) is a progressive disorder in which damage to the heart causes weakening of the cardiovascular system. HF is defined as the inability of the heart to supply sufficient blood to meet the needs of the body. HF is a major cause of mortality in the community. Identifying HF aetiology is crucial when planning interventions aimed to reduce mortality and morbidity.
16 ST. RAPHAEL OF ST. FRANCIS HOSPITAL NSAMBYA
17 AIMS During , 5 non-governmental organizations missions carried out by Italian medical teams (30 weeks) had the opportunity to prospectively collect clinical and echocardiographic data from patients referred to a urban Hospital in Kampala, Uganda. The objective of the study was to provide a hospital-based epidemiological picture of HF.
18 RESULTS Among 217 subjects referred for suspicion of heart disease, 150 were affected by heart disease. Most patients (97; 65%) presented with HF (median age 32 years, IQR 12-65, female 52%). The main cause of HF was RHD (n=29, 30%), mainly related to mitral valve regurgitation (60%). RHD is a complication of rheumatic fever and represents the predominant form of valvular disease affecting children and young adults. Among HF patients affected by RHD, 23 (79%) had an indication for cardiac surgery.
19 CONCLUSIONS RHD still remains the most common cause of HF in Uganda, with late presentation in most cases and heart failure in adulthood. The results should promote efficient cost-effective preventive measures focused on RHD: Screening programmes aimed to increase the community awareness concerning the RHD also promoting a wider diffusion of portable technologies. Education concerning major cardiovascular risk factors and chronic alcohol intake Beyond the preventive strategy there is an actual need for surgical interventions for heart failure related to RHD since cardiac surgery is not available in Uganda.
20 Andrea Z. Beaton, M.D. Children s National Medical Center, Washington DC Echocardiography-Based Screening for the Early Diagnosis of Rheumatic Heart Disease
21 Echocardiography for the Early Diagnosis of RHD Traditionally RHD was only diagnosed through clinical exam Disease was usually advanced
22 Echocardiography for the Early Diagnosis of RHD Finds more cases Is more accurate Can detect very early disease
23 Echocardiography for the Early Diagnosis of RHD Rheumatic Heart Disease found on echocardiogram before clinical symptoms exist is called subclinical RHD
24 Echocardiography for the Early Diagnosis of RHD
25 Echocardiography for the Early Diagnosis of RHD Since 2004 the World Health Organization has recommended echocardiography for RHD screening in high-prevalence regions
26 Echocardiography for the Early Diagnosis of RHD 5006 Available Children enrolled in 6 Screening Sites 4869 Children Screened (97%) 130 Children with Abnormal Screening Echo (2.4%) 72 Total RHD Cases (1.5%)
27 Echocardiography for the Early Diagnosis of RHD 5006 Available Children enrolled in 6 Screening Sites Prevalence rate of 1.5% 4869 Children Screened (97%) 130 Children with Abnormal Screening Echo (2.4%) 72 Total RHD Cases (1.5%)
28 Echocardiography for the Early Diagnosis of RHD 5006 Available Children enrolled in 6 Screening Sites 47 Sub-clinical RHD 4869 Children Screened (97%) 130 Children with Abnormal Screening Echo (2.4%) 72 Total RHD Cases (1.5%)
29 Echocardiography for the Early Diagnosis of RHD Children attending schools with lower socioeconomic representation were more likely Have RHD Have advanced disease Mean age of RHD positive (10.1 yrs) children higher than RHD negative children (9.3 yrs) May have implications for screening protocols
30 Echocardiography for the Early Diagnosis of RHD We are just beginning to learn about patients with subclinical RHD What is the natural history of subclinical RHD? 12-month Follow-Up Data Do they benefit from secondary prophylaxis?
31 Echocardiography for the Early Diagnosis of RHD 43 (60%) children presented for follow-up at 6 months 41 (57%) children presented for follow-up at 12 months % % % 29 58/88 (66%) 75% Definite Probable Possible No Disease Total Patients Follow-up
32 Echocardiography for the Early Diagnosis of RHD 12 Month Disease Progression Definite /58 (22%) showed improvement Probable /58 (12%) showed worsening Possible None 9 3 Unchanged Improved Worsened
33 Echocardiography for the Early Diagnosis of RHD 12 Month Disease Progression Definite 5 2 Probable Resolution of MR Possible None 9 3 Unchanged Improved Worsened
34 Echocardiography for the Early Diagnosis of RHD 12 Month Disease Progression Definite 5 2 New regurgitant murmur Probable Possible None 9 3 Unchanged Improved Worsened
35 Echocardiography for the Early Diagnosis of RHD At 6 months 13/17 (76%) children prescribed penicillin showed >90% compliance At 12 months 8/15 (53%) had >90% compliance 9/9 boarding students receiving PCN from school nurse had 100% compliance at both visits
36 Echocardiography for the Early Diagnosis of RHD Follow-up of children diagnosed with RHD in a school-based echo-screening program is feasible Early follow-up shows dynamic disease development: both improvement and worsening More research is needed into improving rates of compliance with secondary prophylaxis The effectiveness and need of secondary prophylaxis in children with subclinical disease remains unclear
37 Echocardiography for the Early Diagnosis of RHD New evidence-based guidelines will allow for collaborations to determine the significance of sub-clinical disease
38 Echocardiography for the Early Diagnosis of RHD
39 Dr. Abdulkader A. Sharafadden, MMed Head of Cardiac Department at Algomhori Teaching Hospital, Taiz, Yemen Interventional Therapy and the Need for Earlier Intervention
40 Rheumatic Mitral Valve Stenosis An acquired progressive form of valvular heart disease caused by rheumatic fever Characterized by diffuse thickening of mitral valve leaflets, fusion of the commissures, shortening and fusion of the chordae tendineae Resulting in an obstruction of the blood flow from the left atrium to the left ventricle Leaflets Chordae papillary Mitral valve Normal Mitral stenosis
41 Therapy Medical - Prevention of recurrent rheumatic fever, - Prevention and treatment of complications - Monitoring disease progression to allow intervention at the optimal time point. PBMV Interventional - Percutaneous Balloon Mitral Valvuloplasty ( PBMV ) - Surgical intervention
42 1 st of June 2008 to 28 th of February patients
43 Inclusion criteria All patients were admitted and confirmed to have pure rheumatic mitral valve stenosis by echocardiography. Cases with compound and other rheumatic valves lesions were just included for statistical purposes.
44 Distribution of patients with RHD admitted to Cardiology Department at Algomhori Hospital Rheumatic valve lesion Mitral stenosis Pure mitral stenosis Mitral regurgitation Aortic stenosis Aortic regurgitation From Rheumatic Heart Disease (n= 206) % From total cardiac patients (n=1082) % Total RHD %
45 Distribution of sex and mean age within patients with pure Rheumatic Mitral Stenosis Males 28.7 % Females 71.3 % M : F Ratio 1 : 2.4 Mean age ±14.13 years
46 Degree of stenosis in patients with pure Rheumatic Mitral Valve Stenosis Mild 11.5% Severe 51.7% Moderate 36.8%
47 Recurrent Rheumatic Fever in patients with pure Rheumatic Mitral Stenosis Negative 60.9% Positive 39.1%
48 Adherence to secondary prophylaxis for Rheumatic Fever Positive 28.7% Negative 71.3%
49 Complications according to the degree of stenosis Degree of stenosis Complications Mild ( n=10 ) Moderate ( n=32 ) Severe (n=45 ) % % % P Pulmonary Hypertension ( n=83 ) Pulmonary Congestion ( n=45 ) Atrial Fibrillation ( n=35 ) Right Ventricular Failure ( n=17 ) Stroke ( n=11 ) Frank Pulmonary Edema ( n=9 ) Left Atrial Thrombus ( n=3 ) Infective Endocarditis ( n=2 ) Peripheral Embolisation ( n=1 )
50 Hospital stay duration according to complications Hospital Stay Complications <1 week ( n=40 ) 1-2 weeks ( n=39 ) > 2 weeks ( n=8 ) % % % P Pulmonary Hypertension ( n=83 ) Pulmonary Congestion ( n=45 ) Atrial Fibrillation ( n=35 ) Right Ventricular Failure ( n=17 ) Stroke ( n=11 ) Frank Pulmonary Edema ( n=9 ) Left Atrial Thrombus ( n=3 ) Infective Endocarditis ( n=2 ) Peripheral Embolisation ( n=1 )
51 Case fatality according to the degree of Mitral Valve Stenosis Degree of mitral stenosis Alive % Outcome Died % Mild (n= 10) Moderate (n= 32) Severe (n= 45) Total
52 Percentages Case fatality according to complications
53 Percentages Plan of therapy in patients with Mitral Valve Stenosis 60% 50% % 30% 20% % 0% BMVP Surgical intervention Follow up
54 Performance of interventional therapy Surgical BMVP intervention Interventional Therapy Performed 4% Performed Performed 23.9% 34.8% Not performed Not Not performed 64.2% performed 76.1% 96%
55 Conclusions Mitral stenosis was the most common RHD within our community accounted for 57.8% while pure mitral stenosis accounted for 43.2% Females were more affected than males (M:F ratio 1:2.4) The detection rate of the Attack of rheumatic fever was low with only 39.1% and adherence to secondary chemoprophylaxis was weak among patients with only 28.7%..
56 Conclusions Most patients were in a late stage of the disease necessitating interventional therapy Case fatality was 9.2%, all noted among severe degree of stenosis Performance of interventional therapy was far lower than that required (23.9 %)
57 Recommendations Mitral stenosis requires 3 early: Early diagnosis Early prevention Early intervention
58 Recommendations Great efforts must be made to detect the first signs of Rheumatic fever and Rheumatic heart disease as this maybe the only clinically manifested visit at an early stage before it becomes subclinical and so be missed until the progression of disease or complications occur. Any auscultated murmur must be thoroughly investigated by echocardiography because secondary prevention and outcome of the disease relies on accurate case detection.
59 Recommendations Establishing a RHD Surveillance System for a better documentation and registration all over the country to facilitate health care planning. Screening programs for Rheumatic heart disease must be performed among elementary school children by echocardiography.
60 Recommendations Great efforts should be done to implement primary and secondary prevention programs for rheumatic fever and RHD including establishing health educational programs through different media. Advanced cardiac centers must be established throughout the country to facilitate accessibility to appropriate management including interventional therapies with less effort and free of charge.
61 Recommendations Reconsideration of the health strategy applied in Yemen concerning general practioners practice where they should be sent immediately after graduation to central hospitals to gain the adequate experience before sending them for rural services (primary care centers).
62 Benzathine penicillin BMVP Mitral valve replacement 10 years cost 20 years cost 200 $ 2000 $ 5000 $ 400$??????
63 Special Thanks Assoc. Prof. Ali Ahmed Ali Assoc. Prof. Hilal Lashuel Dr. Enas Ali Dammag
64 Q&A Session
Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular
Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular Mitral Regurgitation Anatomy Mechanisms of MR Presentation Evaluation Management Repair Replace Clip
More information5. Management of rheumatic heart disease
5. Management of rheumatic heart disease The fundamental goal in the long-term management of RHD is to prevent ARF recurrences, and therefore, prevent the progression of RHD, and in many cases allow for
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationResults of the RHEUMATIC (Rheumatic Heart Echo Utilization and Monitoring Actuarial Trends in Indian Children) Study
ESC 2010, Stockholm Results of the RHEUMATIC (Rheumatic Heart Echo Utilization and Monitoring Actuarial Trends in Indian Children) Study Anita Saxena, S Ramakrishnan, A Roy, A Krishnan, S Seth, SK Reddy,
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS,
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationTranscatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations. Danny Dvir, MD On behalf of VIVID registry investigators
Transcatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations Danny Dvir, MD On behalf of VIVID registry investigators Introduction Bioprosthetic valves are increasingly implanted in open-heart surgeries.
More informationAtrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
More informationHow should we treat atrial fibrillation in heart failure
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 23/24 Ottobre 2015 How should we treat atrial fibrillation in heart failure Matteo Anselmino Dipartimento Scienze Mediche Città
More informationRight-sided infective endocarditis:tunisian experience
Right-sided infective endocarditis:tunisian experience L. Ammari, A. Ghoubontini, A. Berriche, R. Abdelmalek, S.Aissa, F.Kanoun, B.Kilani, H.Tiouiri Benaissa, T.Ben chaabane Department of Infectious diseases,
More informationSteven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,
More informationAtrial Fibrillation An update on diagnosis and management
Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationHISTORY. Questions: 1. What diagnosis is suggested by this history? 2. How do you explain her symptoms during pregnancy?
HISTORY 33-year-old woman. CHIEF COMPLAINT: months duration. Dyspnea, fatigue and nocturnal wheezing of six PRESENT ILLNESS: At ages 5 and 9, she had migratory arthritis. At age 29, in the third trimester
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationAtherosclerosis of the aorta. Artur Evangelista
Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis
More information5. Diagnosis and management of rheumatic heart disease
5. Diagnosis and management of rheumatic heart disease Introduction Chronic rheumatic valvular heart disease is the long-term result of ARF. It is a disease of poverty and disadvantage. In Australia, the
More informationSurvey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation
Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation On the following pages are a number of questions asking about the conditions under which you would prescribe anticoagulation
More informationClinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b
Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy Statement: Percutaneous
More informationCHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications
CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationUHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationPrevalence of Rheumatic Valvular Heart Disease Among Egyptian School Children: An Echocardiographic Screening
Med. J. Cairo Univ., VoL 81, No. 1, March: 139-144, 2013 www.medicaljournalofcairouniversity.com Prevalence of Rheumatic Valvular Heart Disease Among Egyptian School Children: An Echocardiographic Screening
More informationUpdates to the Alberta Drug Benefit List. Effective January 1, 2016
Updates to the Alberta Drug Benefit List Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationBASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY
BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY American Osteopathic Association and the American College of Osteopathic Internists Specific Requirements For Osteopathic Subspecialty Training In Cardiology
More informationATRIAL FIBRILLATION: Scope of the Problem. October 2015
ATRIAL FIBRILLATION: Scope of the Problem October 2015 Purpose of the Presentation Review the worldwide incidence and prognosis associated with atrial fibrillation (AF) Identify the types of AF, clinical
More informationPopulation Health Management Program
Population Health Management Program Program (formerly Disease Management) is dedicated to improving our members health and quality of life. Our Population Health Management Programs aim to improve care
More informationService Specification Template Department of Health, updated June 2015
Service Specification Template Department of Health, updated June 2015 Service Specification No. : 2 Service: Commissioner Lead: Provider Lead: Period: Anti-coagulation monitoring Date of Review: 31 st
More informationOsama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015
STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015 PROJECT TITLE: Analysis of ECG Exercise Stress Testing and Framingham Risk Score in Chest Pain Patients PRIMARY SUPERVISOR NAME: Dr. Edward Tan DEPARTMENT:
More informationHow To Treat Heart Valve Disease
The Valve Clinic at Baptist Health Madisonville The Valve Clinic at Baptist Health Madisonville Welcome to the Baptist Health Madisonville Valve Clinic at the Jack L. Hamman Heart & Vascular Center. We
More informationStroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012
Faculty Prevention Sharon Ewer, RN, BSN, CNRN Stroke Program Coordinator Baptist Health Montgomery, Alabama Satellite Conference and Live Webcast Monday, May 21, 2012 2:00 4:00 p.m. Central Time Produced
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationAtrial Fibrillation in the ICU: Attempting to defend 4 controversial statements
Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Salmaan Kanji, Pharm.D. The Ottawa Hospital The Ottawa Hospital Research Institute Conflict of Interest No financial, proprietary
More informationEchocardiographic Screening for Rheumatic Heart Disease
REVIEW greview j Echocardiographic Screening for Rheumatic Heart Disease Issues for the Cardiology Community Anita Saxena*, Liesl Zühlke y,z, Nigel Wilson x New Delhi, India; Cape Town, South Africa; and
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationMitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013
Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation Michael Acker, MD For the CTSN Investigators AHA November 2013 Acknowledgements Supported by U01 HL088942 Cardiothoracic
More informationTelemedicine in the Prevention and Monitoring of Heart Disease
Telemedicine in the Prevention and Monitoring of Heart Disease Prof. Dr. med. Friedrich Köhler 26. April 2012 Charité-Universitätsmedizin Berlin Facts Founded in 1710 11 Nobel laureates 12.922 employees
More informationEVALUATION OF MEDICAL RECORDS COMPLETENESS IN THE ADULT CARDIOLOGY CLINIC AT NORK MARASH MEDICAL CENTER
American University of Armenia Center for Health Services Research and Development Nork Marash Medical Center EVALUATION OF MEDICAL RECORDS COMPLETENESS IN THE ADULT CARDIOLOGY CLINIC AT NORK MARASH MEDICAL
More informationon behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
More informationPalpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust
Palpitations & AF Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations Frequent symptom Less than 50% associated with arrhythmia
More informationRequirements for Provision of Outreach Paediatric Cardiology Service
Requirements for Provision of Outreach Paediatric Cardiology Service Dr Shakeel A Qureshi, Consultant Paediatric Cardiologist, Evelina Children s Hospital, London, UK On behalf of British Congenital Cardiac
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationAtrial fibrillation: medicines to help reduce your risk of a stroke what are the options?
Patient decision aid Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options? http://guidance.nice.org.uk/cg180/patientdecisionaid/pdf/english Published: June 2014 About
More informationTreatments to Restore Normal Rhythm
Treatments to Restore Normal Rhythm In many instances when AF causes significant symptoms or is negatively impacting a patient's health, the major goal of treatment is to restore normal rhythm and prevent
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /
More informationNational Medicines Information Centre
National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 www.nmic.ie THE CONTEMPORARY MANAGEMENT OF ATRIAL FIBRILLATION VOLUME 12 NUMBER 3 2006
More informationSTROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE
STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE CASE REPORT: ACUTE STROKE MANAGEMENT 90 YEAR OLD WOMAN, PREVIOUSLY ACTIVE AND INDEPENDENT, CHRONIC ATRIAL FIBRILLATION,
More informationAtrial Fibrillation The Basics
Atrial Fibrillation The Basics Family Practice Symposium Tim McAveney, M.D. 10/23/09 Objectives Review the fundamentals of managing afib Discuss the risks for stroke and the indications for anticoagulation
More informationDiagnostic and Therapeutic Procedures
Diagnostic and Therapeutic Procedures Diagnostic and therapeutic cardiovascular s are central to the evaluation and management of patients with cardiovascular disease. Consistent with the other sections,
More informationCardiovascular diseases. pathology
Cardiovascular diseases pathology Atherosclerosis Vascular diseases A disease that results in arterial wall thickens as a result of build- up of fatty materials such cholesterol, resulting in acute and
More information2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.
DISCLOSURES I have no relevant financial relationships to disclose. Cardiac Evaluation of Potential Solid Organ Transplant Recipients Michele Hamilton, MD Director, Heart Failure Program Cedars Sinai Heart
More informationACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY
Care Pathway Triage category ATRIAL FIBRILLATION PATHWAY ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY AF/ FLUTTER IS PRIMARY REASON FOR PRESENTATION YES NO ONSET SYMPTOMS OF AF./../ TIME DURATION OF AF
More informationEducational Goals & Objectives
Educational Goals & Objectives The Cardiology rotation will provide the resident with an understanding of cardiovascular physiology and its broad systemic manifestations. The resident will have the opportunity
More information06 Validation of risk prediction model
HA Territory-wide PCI Audit 2003-06 06 Validation of risk prediction model PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 2007 Background Participants: All HA hospitals via
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationPotential Causes of Sudden Cardiac Arrest in Children
Potential Causes of Sudden Cardiac Arrest in Children Project S.A.V.E. When sudden death occurs in children, adolescents and younger adults, heart abnormalities are likely causes. These conditions are
More informationNon-Valvular Atrial Fibrillation & Anticoagulation Therapy: An Actuarial Study of the Medicare Population
Non-Valvular Atrial Fibrillation & Anticoagulation Therapy: An Actuarial Study of the Medicare Population Prepared by: Milliman, Inc., NY Kathryn Fitch, RN, MEd Principal and Healthcare Management Consultant
More informationStroke Prevention in Primary Care
Stroke Prevention in Primary Care ANNE LINDSTROM, APN, FNP-BC, SCRN Disclosures I have no disclosures. Objectives Describe tools available to estimate patient risk of stroke Review non-modifiable risk
More informationHeart valve repair and replacement
16 Heart valve repair and replacement 222 Valvular heart disease can be treated in a variety of ways: valve replacement, in which an artificial (prosthetic) heart valve is implanted surgically to replace
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationHealthCare Partners of Nevada. Heart Failure
HealthCare Partners of Nevada Heart Failure Disease Management Program 2010 HF DISEASE MANAGEMENT PROGRAM The HealthCare Partners of Nevada (HCPNV) offers a Disease Management program for members with
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationContact centred strategies to reduce transmission of M. leprae
Contact centred strategies to reduce transmission of M. leprae Jan Hendrik Richardus, MD, PhD Department of Public Health Erasmus MC, University Medical Center Rotterdam The Netherlands Outline lecture
More informationATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014
ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014 Facts 4 million or so people have atrial fibrillation 16 billion dollars spent yearly in USA 30% of strokes attributable to AF and AFL 3-5
More informationINHERIT. The Lancet Diabetes & Endocrinology In press
INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy a Randomized Intervention Trial with losartan Anna Axelsson, Kasper Iversen, Niels Vejlstrup, Carolyn
More informationChristopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona
Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary
More informationInpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
More informationDurability of mitral valve repair for mitral regurgitation due to degenerative mitral valve disease
Keynote Lecture Series Durability of mitral valve repair for mitral regurgitation due to degenerative mitral valve disease Tirone E. David Division of Cardiovascular Surgery, Peter Munk Cardiac Centre,
More informationHot Line Session at European Society of Cardiology (ESC) Congress 2014:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily
More informationDental Work and the Risk of Bacterial Endocarditis
Variety Children s Heart Centre Dental Work and the Risk of Bacterial Endocarditis Certain heart conditions and structural defects increase the risk of developing endocarditis (a heart valve infection)
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationThe Role of Insurance in Providing Access to Cardiac Care in Maryland. Samuel L. Brown, Ph.D. University of Baltimore College of Public Affairs
The Role of Insurance in Providing Access to Cardiac Care in Maryland Samuel L. Brown, Ph.D. University of Baltimore College of Public Affairs Heart Disease Heart Disease is the leading cause of death
More informationCardiac Masses and Tumors
Cardiac Masses and Tumors Question: What is the diagnosis? A. Aortic valve myxoma B. Papillary fibroelastoma C. Vegetation from Infective endocarditis D. Thrombus in transit E. None of the above Answer:
More informationAtrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology
Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of
More informationGRASP-AF Coming to a PCT near you.
GRASP-AF Coming to a PCT near you. ADAS Anticoagulation dosing advisory service Blackpool Teaching Hospitals Trust Sean O'Brien; Anticoagulation Specialist BMS Grasp-AF and the implications on our Anticoagulation
More informationMaking the Health Check work for you
Making the Health Check work for you Atrial Fibrillation and the GRASP toolkit (Guidance on Risk Assessment and Stroke Prevention ) Dr. Indira Natarajan Consultant Stroke Physician University Hospital
More informationRobert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Judith Long, MD,RWJCS Perelman School of Medicine Philadelphia Veteran Affairs Medical Center Background Objective Overview Methods
More informationManagement of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery
Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery Srinivasan Rajagopal M.D. Assistant Professor Division of Cardiothoracic Anesthesia Objectives Describe the pathophysiology
More informationSpecific Basic Standards for Osteopathic Fellowship Training in Cardiology
Specific Basic Standards for Osteopathic Fellowship Training in Cardiology American Osteopathic Association and American College of Osteopathic Internists BOT 07/2006 Rev. BOT 03/2009 Rev. BOT 07/2011
More informationThe Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (2nd edition)
QRGs Print Contents Basic search Advanced search Previous page Next page The Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (2nd edition)
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationAnticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
More informationAll Patient Refined DRGs (APR-DRGs) An Overview. Presented by Treo Solutions
All Patient Refined DRGs (APR-DRGs) An Overview Presented by Treo Solutions Presentation Highlights History of inpatient classification systems APR-DRGs: what they are, how they work, and why they are
More informationLow-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity
Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea
More informationOHTAC Recommendation
OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the
More informationA Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation
Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation
More informationCommissioning effective anticoagulation services for the future
anticoagulation ( ) UK Commissioning effective anticoagulation services for the future A resource pack for commissioners The development of this commissioning toolkit was supported by Bayer HealthCare.
More informationCommon types of congenital heart defects
Common types of congenital heart defects Congenital heart defects are abnormalities that develop before birth. They can occur in the heart's chambers, valves or blood vessels. A baby may be born with only
More informationMar. 31, 2011 (202) 690-6145. Improving Quality of Care for Medicare Patients: Accountable Care Organizations
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Room 352-G 200 Independence Avenue, SW Washington, DC 20201 Office of Media Affairs MEDICARE FACT SHEET FOR IMMEDIATE RELEASE
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More information17 Endocarditis. Infective endocarditis
17 Endocarditis 234 Endocarditis refers to inflammation of the endocardium, the inner layer of the heart (including the heart valves). Endocarditis can be: infective (e.g. bacterial, fungal) non-infective
More informationListen to Your Heart. What Everyone Needs To Know About Atrial Fibrillation & Stroke. The S-ICD System. The protection you need
Listen to Your Heart The S-ICD System What Everyone Needs To Know About Atrial Fibrillation & Stroke The protection you need without Stroke. touching Are you your at heart risk? Increase your knowledge.
More information